Compositions and methods of phospholipase A2 receptor chimeric autoantibody receptor T cells
AssigneeThe Trustees of the University of Pennsylvania
InventorsSaar Gill, Jonathan Hogan, Aimee S. Payne, Baomei Wang
Life of this patent
Estimating the term…
Abstract
The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.
Claims18
An isolated polynucleotide encoding a chimeric autoantibody receptor (CAAR), wherein the CAAR comprises:
- (i) an extracellular domain comprising a phospholipase A2 receptor (PLA2R) autoantigen comprising the amino acid sequence of SEQ ID NO:
- 59;
- (ii) a CD8 alpha chain transmembrane domain;
- (iii) a 4-1BB intracellular domain;
- and
- (iv) a CD3 zeta signaling domain.
A chimeric autoantibody receptor (CAAR) comprising:
- (i) an extracellular domain comprising a phospholipase A2 receptor (PLA2R) autoantigen comprising the amino acid sequence of SEQ ID NO:
- 59;
- (ii) a CD8 alpha chain transmembrane domain;
- (iii) a 4-1BB intracellular domain;
- and
- (iv) a CD3 zeta signaling domain.
Dependencies are inferred from the claim text.